ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Aerie Pharmaceuticals Inc

Aerie Pharmaceuticals Inc (AERI)

15.25
0.00
(0.00%)
Closed November 17 4:00PM
0.00
0.00
(0.00%)

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
15.25
Bid
15.24
Ask
14.79
Volume
-
0.00 Day's Range 0.00
0.00 52 Week Range 0.00
Previous Close
15.25
Open
-
Last Trade
Last Trade Time
Average Volume (3m)
-
Financial Volume
-
VWAP
-

AERI Latest News

Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company’s Ophthalmic Pharmaceutical Business

Leveraging Alcon’s robust commercial capabilities and resources to drive further growth and access to Rocklatan and Rhopressa Acquisition adds pharmaceutical research and development...

Small-Cap Catalyst Pharmaceuticals Is Among Market’s Best Price Performers

Small-cap biotech Catalyst Pharmaceuticals recently joined the S&P 600 index, which means institutions must own shares to track the index The company has a steady history of price appreciation...

Aerie Pharmaceuticals Shares Rise 34% After Alcon Buyout Offer

By Chris Wack Aerie Pharmaceuticals Inc. shares were up 34% to $14.91 in premarket trading after the company said it was being bought by Alcon AG for $15.25 a share. The purchase price represents...

Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio

Builds on Alcon’s existing commercial expertise in the estimated $20 billion global ophthalmic pharmaceutical segment1 Adds Rocklatan® and Rhopressa®, and a pipeline of several clinical and...

Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit Glaucoma Innovation Showcase

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that Tom Mitro, President and Chief Operating Officer presented an overview on Aerie’s glaucoma...

Aerie Pharmaceuticals Announces Positive Phase 3 Topline Results for Netarsudil Ophthalmic Solution 0.02% Clinical Trial in Japan

Netarsudil Ophthalmic Solution 0.02% Once Daily Demonstrated Superiority to Ripasudil 0.4% Twice Daily Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company, today...

Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit Retina Innovation Showcase

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that Casey Kopczynski, Ph.D., Chief Scientific Officer presented an overview on Aerie’s retina...

Aerie Pharmaceuticals Announces Presentation at the 39th Annual Scientific Meeting of the American Society of Retina Specialists

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that topline results from the AR-1105 (dexamethasone intravitreal implant) Phase 2 clinical trial...

Aerie Pharmaceuticals to Participate in the Cantor Global Healthcare Conference

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of...

Aerie Pharmaceuticals, Inc. Announces the Appointment of Interim Executive Chair and Departure of Chairman and CEO

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that it is executing its succession plan for its long-serving Chairman and CEO and that effective...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CEROCERo Therapeutics Holdings Inc
$ 0.2853
(52.40%)
1.17B
CYCNCyclerion Therapeutics Inc
$ 2.5306
(42.97%)
11.99M
SPPLSIMPPLE Ltd
$ 1.2503
(41.60%)
165.69M
PULMPulmatrix Inc
$ 6.5586
(39.54%)
5.37M
ZTEKZentek Ltd
$ 1.2574
(29.96%)
309.67k
TFFPTFF Pharmaceuticals Inc
$ 0.376101
(-76.49%)
9.23M
EYENEyenovia Inc
$ 0.10185
(-70.05%)
51.98M
CTXRCitius Pharmaceuticals Inc
$ 0.1974
(-39.89%)
11.15M
VVPRVivoPower International PLC
$ 0.8151
(-39.62%)
2.3M
IPWiPower Inc
$ 0.7302
(-39.15%)
1.13M
CEROCERo Therapeutics Holdings Inc
$ 0.2853
(52.40%)
1.15B
ELABElevai Labs Inc
$ 0.0211
(-19.47%)
377.69M
NVDANVIDIA Corporation
$ 141.98
(-3.26%)
244.07M
SPPLSIMPPLE Ltd
$ 1.2503
(41.60%)
164.49M
STISolidion Technology Inc
$ 0.44
(25.71%)
139.46M

AERI Discussion

View Posts
dealerschool2006 dealerschool2006 3 years ago
Temp set back for $AERI today...
👍️0
bobbleheadtwin bobbleheadtwin 3 years ago
SKYE + AERI = $$$$
👍️0
Johnny_C Johnny_C 4 years ago
Looking better. Gonna be a long haul back up though
👍️0
whytestocks whytestocks 4 years ago
News: $AERI Aerie Pharmaceuticals Inc (AERI) Q2 2020 Earnings Call Transcript

Image source: The Motley Fool. Aerie Pharmaceuticals Inc   (NASDAQ: AERI) Q2 2020 Earnings Call Aug 7, 2020 , 11:00 a.m. ET Operator Continue reading

Find out more AERI - Aerie Pharmaceuticals Inc (AERI) Q2 2020 Earnings Call Transcript
👍️0
Johnny_C Johnny_C 5 years ago
Tempted to buy more here - but holding off
👍️0
Johnny_C Johnny_C 5 years ago
Here’s hoping. Seems oversold and we rentered
👍️0
whytestocks whytestocks 5 years ago
News: $AERI Aerie Pharmaceuticals Inc. (NASDAQ:AERI) Short Squeeze

Over the past twenty days of trading, Aerie Pharmaceuticals Inc. (NASDAQ: AERI), from October 30, 2019 to November 26, 2019 there is a potential Sh...

Got this from AERI - Aerie Pharmaceuticals Inc. (NASDAQ:AERI) Short Squeeze
👍️0
whytestocks whytestocks 5 years ago
$AERI good read Aerie Pharmaceuticals Inc Nasdaq Aeri Short Squeeze
👍️0
Johnny_C Johnny_C 5 years ago
Oh boy. 250 mil raise on the way. Should be a screaming but now. Stock pps with 2 blockbuster approvals lower than with none. There has been a bit of dilution though.

Very tough bringing drugstore to market even if they are blockbuster status
👍️0
Johnny_C Johnny_C 5 years ago
Looks like a fantastic buy right now for those with patience. Cash burn rough if they keep up the market it themselves model.

First purchase here was 11 sold at 35. Bought back at 17 sold most of position at 69 average although hung on to 3000 shares thinking it was going to 100 in a buyout.

This stock has been great and will be again
👍️0
jdlamont jdlamont 5 years ago
They would be smart to acquire EYEN to become the force d' major
👍️0
whytestocks whytestocks 6 years ago
News: $AERI Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial in Japan Designed to Support Requirements for Future Regulatory Filing

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announ...

Got this from https://marketwirenews.com/news-releases/aerie-pharmaceuticals-initiates-netarsudil-ophthalmic-solution-phase-2-clinical-trial-in-japan-designed-to-support-requirements-for-future-regulatory-filing-7860488.html
👍️0
Johnny_C Johnny_C 6 years ago
$80.00 pps in latest coverage. Puts it at near 4 bil market cap if it happens
👍️0
Johnny_C Johnny_C 6 years ago
Kaboom. Aeri new drug approved. Very good fuidance
👍️0
Johnny_C Johnny_C 6 years ago
Sure sounds like they are going to market the new drug themselves once approved. Hope not. Approval will Either an optimal time for a deal or to exit stock. It has been a very very good investment.
👍️0
Johnny_C Johnny_C 6 years ago
recovered $10.00 in a week. With deals heating up this worth a look, off high of 70 and second product could be approved anytime first half
👍️0
Johnny_C Johnny_C 6 years ago
AERI coverage just keeps getting better.

Aerie Pharmaceuticals May Revolutionize Glaucoma Treatmenthttps://finance.yahoo.com/news/aerie-pharmaceuticals-may-revolutionize-glaucoma-110100052.html
👍️0
Johnny_C Johnny_C 6 years ago
This puppy could hit 100 next year, that would make it a 10 bagger. Can't wait to hear whats up on earnings call
👍️0
Johnny_C Johnny_C 7 years ago
Second drug looks to be much improved. Some are saying they still could be bought out although their actions are not encouraging.
👍️0
Johnny_C Johnny_C 7 years ago
They are raising 75 mil more and going forward hiring salespeople. They should be a take out target and only having one product that is new is a difficult sell. Even if a Company like Allergan bought them AGN would lose money the first 24 months.

At least they are raising money in the most responsible way a Company can do it.

we were in at 9 average out at 33, went back in 1t 16 and out at 65. All in 2 years. back in at 58 for a smaller amount.

👍️0
jones99 jones99 7 years ago
Seems like Buyout is the only option now. Most of Bios now are sell the approval or News or Offering
👍️0
Johnny_C Johnny_C 7 years ago
WOW... what timimg.. AERI halted and drug approved 2 months early. Most likely no warning label.

WOW WOW WOW
👍️0
Johnny_C Johnny_C 7 years ago
Back in - still concerned about labeling but AERI could be a prime take out with tax reform. If not, will be out when news breaks from FDA
👍️0
Johnny_C Johnny_C 7 years ago
Just a few months to go for the big news. I have been an Aeri supporter for almost 2 years. Bought at 10 sold at 32, rebought at 17 sold at average of 62.

Entered very small at 59.

What is problematic is the lack of deals and mergers being done. They look to have 2 superstar blockbusters and the stock may very well be 80 to 100 if a buyout were to occur.

That is less likely though as they are hiring their own sales force. Not only does that present the problem of salesman having a one trick pony product for now, but they have zero experience running a sales team. Even hiring experienced people from big pharma is not encouraging as they are use to having a portfolio of drugs, established relationships and a huge marketing budget. There is a possibility of the product having a label as well.

This is not a Gilead situation where a drug takes over a market immediately. Most small biotech’s lose money for at least 3 years, and lose a lot of money. Aeri could bled 100’s if millions of dollars before it reaches us profitable, and the over under on pivoting to profits is 3.5 years.

The upside is that Aeri could be a billion dollar drug, or more. We bought Aeri for turnaround and buyout just like rite aid, Salix, Receptos, Sarepta BMY.

Aeri seemed a perfect fit for AGN, but it is not looking like that now. Tax reform doesn’t benefit AGN. Maybe they will get bought out but not optimistic at this point.
👍️0
Johnny_C Johnny_C 7 years ago
Analysts now calling up to 80. Might buy back now that things have settled in
👍️0
Johnny_C Johnny_C 7 years ago
Hopefully approved without a label.
👍️0
Johnny_C Johnny_C 7 years ago
Upon reading the one no vote is very bad because that opinion is bad. Thinking gap up and approval but label will be curious. Waiting for press release.
👍️0
Johnny_C Johnny_C 7 years ago
Oops. Sold to soon. Great news. Safety received a 9 to 1 positive bote
👍️0
Johnny_C Johnny_C 7 years ago
Aeri halted. Could be good news, seems like that anyway
👍️0
Johnny_C Johnny_C 7 years ago
In since $11.00. Time to say goodbye for now.

This is at 2.3 bil market cap. A billion dollar drug could push this to 100 but happy with 2 yr win. Might buy on dips
👍️0
Johnny_C Johnny_C 7 years ago
Meeting is on, my reading is drug is effective and discussion will be about safety
👍️0
Johnny_C Johnny_C 7 years ago
Aeri flying. Data so good no need for fda review friday
👍️0
Johnny_C Johnny_C 7 years ago
Good day for Aeri. Maybe profit taking over in anticipation of Friday.

👍️0
Johnny_C Johnny_C 7 years ago
Big day Friday. Was a steal when dipped under 50
👍️0
realfast95 realfast95 7 years ago
The FDA's Dermatologic and Ophthalmic Drugs Advisory Committee will meet on October 13 to review and discuss Aerie Pharmaceuticals' (AERI -5.5%) New Drug Application seeking approval for Rhopressa (netarsudil ophthalmic solution) to reduce intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

The FDA's action date is February 28, 2018.
👍️0
Johnny_C Johnny_C 7 years ago
Decent correction. Upcoming FDA will be huge. Could be moderate safety profile issue, if not will be interesting where the next leg takes this
👍️0
Johnny_C Johnny_C 7 years ago
Hit new high this week. Not a bad run from first buying at $9.00

Next month big meeting with FDA...Fingers crossed.
👍️0
Johnny_C Johnny_C 7 years ago
Aeri creeping back towards ALL TIME highs... Winner Winner!
👍️0
Johnny_C Johnny_C 7 years ago
Still holding, bought at 9 sold at 32. Bought back at 16. Eventually there will be pharma but it's again and this is still attractive
👍️0
Don'tDrinkTheKoolAid Don'tDrinkTheKoolAid 8 years ago
I wonder where those shorts bought back how much did they lose?
👍️0
DorseyE DorseyE 8 years ago
Check this out
RDHL has1 NDA filling & 2 phase 3 results due by 6/30/2017 + 1 phase 2 due due by 7/31/2017///
👍️0
Johnny_C Johnny_C 8 years ago
we always thought they would be a good buyout candidate.. 2017 might be the year
👍️0
stocktrademan stocktrademan 8 years ago
Looks good daily weekly and monthly...keep pulling in the profits!

...nice ascending triangle breakout pattern here...good things in store... http://goo.gl/i0RzyE



👍️0
Johnny_C Johnny_C 8 years ago
Nearly touched 45.... we got in at 8 Good things siillmto come
👍️0
Johnny_C Johnny_C 8 years ago
How is short position going? Been in big time since the first collapse to 9 and loaded the bus. instinct tells me this will get some type of offer with a 6 or higher in front of it in 2017. could correct a little first but the data seems pretty good.
👍️0
diannedawn diannedawn 8 years ago
Is this the new Seth Shaw pump job?

ROTFLMAO
It's being touted on other boards...
So I'm guessing it is...
👍️0
Johnny_C Johnny_C 8 years ago
OUch....:). I don't think Inwould be hopping on the short train just yet. We got in on a the first massive drop, from 33 to 8 in a day. That was based on bad results due to such a big reach, as soon as they amended it popped right back to the 30's. The recent drop was the whole biotech sector getting clobbered with the Valeant mess. now they have submitted and also have another promising drug.

I think you are going to see some of the big dogs go on buying spree again, AGN, PFE GILD. This is right in AGN's wheelhouse for both drugs
👍️0
stocktrademan stocktrademan 8 years ago
fast and steady profit scan AERI bullish 37.74



normal chart


log chart

👍️0
skidoo31 skidoo31 8 years ago
Ouch
👍️0
bigboard bigboard 8 years ago
Just added to my short position. This has been pumped on HOT AIR
go short, eventually it will crash hard
👍️0

Your Recent History

Delayed Upgrade Clock